Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Beatriz Garcia is active.

Publication


Featured researches published by Beatriz Garcia.


Clinical Cancer Research | 2008

Effective Inhibition of the Epidermal Growth Factor/Epidermal Growth Factor Receptor Binding by Anti-Epidermal Growth Factor Antibodies Is Related to Better Survival in Advanced Non -Small-Cell Lung Cancer Patients Treated with the Epidermal Growth Factor Cancer Vaccine

Beatriz Garcia; Elia Neninger; Ana de la Torre; Idrissa Leonard; Rocío Martínez; Carmen Viada; G. Gonzalez; Zaima Mazorra; Agustin Lage; Tania Crombet

Purpose: Epidermal growth factor (EGF) might be a suitable immunotherapeutic target in non–small-cell lung cancer (NSCLC). Our approach consists of active immunotherapy with EGF. The aim of the study is to characterize the humoral response and its effects on signal transduction in relation with the clinical outcome. Experimental Design: Eighty NSCLC patients treated with first-line chemotherapy were randomized to receive the EGF vaccine or supportive care. EGF concentration in sera, anti-EGF antibodies and their capacity to inhibit the binding between EGF/EGF receptor (EGFR), and the EGFR phosphorylation were measured. Results: Seventy-three percent of vaccinated patients developed a good antibody response, whereas none of the controls did. In good antibody-responder patients, self EGF in sera was significantly reduced. In 58% of vaccinated patients, the post-immune sera inhibited EGF/EGFR binding; in the control group, no inhibition occurred. Post-immune sera inhibited the EGFR phosphorylation whereas sera from control patients did not have this capacity. Good antibody-responder patients younger than 60 years had a significantly better survival. A high correlation between anti-EGF antibody titers, EGFR phosphorylation inhibition, and EGF/EGFR binding inhibition was found. There was a significantly better survival for vaccinated patients that showed the higher capacity to inhibit EGF/EGFR binding and for those who showed an immunodominance by the central region of EGF molecule. Conclusions: Immunization with the EGF vaccine induced neutralizing anti-EGF antibodies capable of inhibiting EGFR phosphorylation. There was a significant positive correlation between antibody titers, EGF/EGFR binding inhibition, immunodominance of anti-EGF antibodies, and survival in advanced NSCLC patients.


Clinical Cancer Research | 2016

A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small-Cell Lung Cancer Patients

Pedro C. Rodriguez; Xitlally Popa; Odeth Martinez; Silvia Mendoza; Eduardo Santiesteban; Tatiana Crespo; Rosa M. Amador; Ricardo Fleytas; Soraida Acosta; Gala N. Romero; Ana de la Torre; Mireysi Cala; Lina Arzuaga; Loisel Vello; Delmairis Reyes; Niurka Futiel; Yanine Otero; Teresa Sabates; Mauricio Catalá; Yoanna I Flores; Beatriz Garcia; Carmen Viada; Patricia Lorenzo-Luaces; Maria A. Marrero; Liuba Alonso; Jenelin Parra; Nadia Aguilera; Yaisel Pomares; Patricia Sierra; Gryssell Rodriguez

Purpose: EGFR is a well-validated target for patients with non–small cell lung cancer (NSCLC). CIMAvax-EGF is a therapeutic cancer vaccine composed of human recombinant EGF conjugated to a carrier protein and Montanide ISA51 as adjuvant. The vaccine is intended to induce antibodies against self EGFs that block EGF–EGFR interaction. Experimental Design: To evaluate overall survival, safety, immunogenicity, and EGF concentration in serum after CIMAvax-EGF, a randomized phase III trial was done in patients with advanced NSCLC. Four to 6 weeks after first-line chemotherapy, 405 patients with stage IIIB/IV NSCLC were randomly assigned to a vaccine group, which received CIMAvax-EGF or a control group, treated with best supportive care. Results: Long-term vaccination was very safe. Most frequent adverse reactions were grade 1 or 2 injection-site pain, fever, vomiting, and headache. Vaccination induced anti-EGF antibodies and decreased serum EGF concentration. In the safety population, median survival time (MST) was 10.83 months in the vaccine arm versus 8.86 months in the control arm. These differences were not significant according the standard log rank (HR, 0.82; P = 0.100), but according a weighted log rank (P = 0.04) that was applied once the nonproportionality of the HR was verified. Survival benefit was significant (HR, 0.77; P = 0.036) in the per-protocol setting (patients receiving at least four vaccine doses): MST was 12.43 months for the vaccine arm versus 9.43 months for the control arm. MST was higher (14.66 months) for vaccinated patients with high EGF concentration at baseline. Conclusions: Switch maintenance with CIMAvax-EGF was well tolerated and significantly increased MST of patients that completed induction vaccination. Baseline EGF concentration predicted survival benefit. Clin Cancer Res; 22(15); 3782–90. ©2016 AACR.


Journal of Immune Based Therapies and Vaccines | 2011

Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients

Pedro C. Rodriguez; Elia Neninger; Beatriz Garcia; Xitlally Popa; Carmen Viada; Patricia Lorenzo Luaces; G. Gonzalez; Agustin Lage; Enrique Montero; Tania Crombet

The prognosis of patients with advanced non small cell lung (NSCLC) cancer remains dismal. Epidermal Growth Factor Receptor is over-expressed in many epithelial derived tumors and its role in the development and progression of NSCLC is widely documented. CimaVax-EGF is a therapeutic cancer vaccine composed by human recombinant Epidermal Growth Factor (EGF) conjugated to a carrier protein, P64K from Neisseria Meningitides. The vaccine is intended to induce antibodies against self EGF that would block EGF-EGFR interaction. CimaVax-EGF has been evaluated so far in more than 1000 advanced NSCLC patients, as second line therapy. Two separate studies were compared to assess the impact of high dose vaccination at multiple anatomic sites in terms of immunogenicity, safety and preliminary efficacy in stage IIIb/IV NSCLC patients. In both clinical trials, patients started vaccination 1 month after finishing first line chemotherapy. Vaccination at 4 sites with 2.4 mg of EGF (high dose) was very safe. The most frequent adverse events were grade 1 or 2 injection site reactions, fever, headache and vomiting. Patients had a trend toward higher antibody response. The percent of very good responders significantly augmented and there was a faster decrease of circulating EGF. All vaccinated patients and those classified as good responders immunized with high dose at 4 sites, had a large tendency to improved survival.


Frontiers in Immunology | 2017

T Cell Subpopulations in Healthy Elderly and Lung Cancer Patients: Insights from Cuban Studies

Danay Saavedra; Beatriz Garcia; Agustin Lage

The senescence of the immune system and the risk of cancer increase with aging. Age itself entails changes in the immune system, which are related to a decrease in thymic output of naïve lymphocytes, an accumulation of chronic antigenic load, notably chronic viral infections such as cytomegalovirus (CMV), and replicative senescence of lymphocytes. These changes could eventually contribute to cancer risk and affect the response to cancer treatment. However, several confounding factors make it difficult to draw a picture of causal relationships. Studies in diverse human populations could contribute to clarify these complex relationships. Here, we summarize the current knowledge about the senescence of the T cells, the relationship with CMV infection, cancer, and cancer treatment. We also review the results of a series of studies performed in Cuba whose population is characterized by the unusual combination of long life expectancy and high antigenic load, including high seroprevalence of CMV, typical of tropical countries. Although immunosenescence affects almost all components and functions of the immune response, its most salient feature is a decrease in numbers and proportions of naïve CD8+ T lymphocytes and an accretion of terminally differentiated CD8+ T lymphocytes. These features were confirmed by the Cuban studies, but interestingly a clear gender effect also appeared. Moreover, as aging is a global phenomenon, a fast increase in elderly with malignancies is expected; therefore, the evaluation of patient’s immune status would support the decision of treating them with immunotherapy and predict the efficacy of such treatments, thereby improving benefits for the patients.


Journal of Clinical Oncology | 2004

Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: Analysis of pooled data from three clinical trials

G. Gonzalez; Carmen Viada; Elia Neninger; Tania Crombet; Idrissa Leonard; Beatriz Garcia; Agustin Lage

2548 Background: During the last 10 years we have studied the effect of vaccination against self EGF, both in the preclinical setting, and in several pilot clinical trials in advanced non-small cell lung cancer (NSCLC) patients. Here, we undertake the analysis of aggregated data from these trials, addressing particularly the issue of the relationship between immunization and survival. METHODS Pooled data from 3 pilot clinical trials in 75 patients, considered not amenable to any other modality of onco-specific treatment, were used. For survival analysis, 27 NSCLC patients were considered as a non-randomized concurrent control group. This group of patients has features which make it adequate for comparison: compliance with inclusion criteria, simultaneity in time, and treatment in the same hospital by the same physician staff. Vaccination using different adjuvants (alum and Montanide ISA51), cyclophosphamide pre-treatment or not, as well as different dosages of the Vaccine were compared. RESULTS On vaccinated patients, 80% showed seroconversion, of which 47% developed a good antibody (Ab) response. Geometric mean of maximal Ab titers was 1:3949 (sera dilution). Adjuvant, vaccine dose and cyclophosphamide pre-treatment significantly influenced immunogenicity whereas the other analyzed variables (sex, age, clinical stage, previous treatment) did not. The immune response was short lasting (2.64 +/- 1.89 months) and non-boostable. To maintain Ab titers continuous re-immunizations were required. No serious adverse events were registered. Vaccinated patients survived significantly more (mean: 9.13 months; median: 8 months) than the control group (mean: 4.85 months; median: 4.53 months) (p=0.0003). Patients who seroconverted survived significantly more than patients who did not. Patients with good Ab response showed a significant improvement in survival as compared with those with poor Ab response. CONCLUSIONS Vaccination with EGF was safe, immunogenic and improved survival in advanced NSCLC patients as compared with concurrent controls. These results are currently being verified in a randomized trial. No significant financial relationships to disclose.


Hybridoma | 2007

Biological Activity In Vitro of Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies with Different Affinities

Arlhee Diaz Miqueli; Rancés Blanco; Beatriz Garcia; Teresita Badia; Ana E. Batista; Ruby Alonso; Enrique Montero


Cancer Immunology, Immunotherapy | 2016

Biomarkers related to immunosenescence: relationships with therapy and survival in lung cancer patients

Danay Saavedra; Beatriz Garcia; Patricia Lorenzo-Luaces; Amnely González; Xitlally Popa; Karla P. Fuentes; Zaima Mazorra; Tania Crombet; Elia Neninger; Agustin Lage


Biotecnología Aplicada | 2009

CIMAvax-EGF: A novel therapeutic vaccine for advanced lung cancer

G. Gonzalez; Agustin Lage; Tania Crombet; Gryssel Rodríguez; Beatriz Garcia; Ariadna Cuevas; Lisel Viña; Norkis Arteaga; Elia Neninger


Journal of Clinical Oncology | 2005

Vaccination with EGF active immunotherapy improves survival in advanced non small cell lung cancer (NSCLC) patients: Interim analysis of a randomized phase II trial

Elia Neninger; Tania Crombet; Marta Osorio; Mauricio Catalá; Ana de la Torre; Idrissa Leonard; Beatriz Garcia; P. Marinello; G. Gonzalez; Agustin Lage


Journal of Clinical Oncology | 2004

Vaccination with epidermal growth factor (EGF) for non small cell lung cancer (NSCLC) therapy: Preliminary results from a randomized phase II clinical trial

Tania Crombet; Elia Neninger; Marta Osorio; M. Catala; Ana de la Torre; Idrissa Leonard; Beatriz Garcia; G. Gonzalez; Rolando Pérez; Agustin Lage

Collaboration


Dive into the Beatriz Garcia's collaboration.

Top Co-Authors

Avatar

Agustin Lage

Center of Molecular Immunology

View shared research outputs
Top Co-Authors

Avatar

Tania Crombet

Center of Molecular Immunology

View shared research outputs
Top Co-Authors

Avatar

Carmen Viada

Center of Molecular Immunology

View shared research outputs
Top Co-Authors

Avatar

Elia Neninger

Hermanos Ameijeiras Hospital

View shared research outputs
Top Co-Authors

Avatar

G. Gonzalez

Center of Molecular Immunology

View shared research outputs
Top Co-Authors

Avatar

Xitlally Popa

Center of Molecular Immunology

View shared research outputs
Top Co-Authors

Avatar

Pedro C. Rodriguez

Center of Molecular Immunology

View shared research outputs
Top Co-Authors

Avatar

Patricia Lorenzo-Luaces

Center of Molecular Immunology

View shared research outputs
Top Co-Authors

Avatar

Zaima Mazorra

Center of Molecular Immunology

View shared research outputs
Top Co-Authors

Avatar

Amnely González

Center of Molecular Immunology

View shared research outputs
Researchain Logo
Decentralizing Knowledge